Name: Cys-MC-VC-PAB-MMAE
Brand: BOC Sciences
Rating: 5 (1 reviews)

Size

Price

Stock

Quantity

$--

In stock

Synonyms

Cysteine-vc-MMAE; N-[6-(3-{[(2R)-2-Amino-2-carboxyethyl]sulfanyl}-2,5-dioxo-1-pyrrolidinyl)hexanoyl]-L-valyl-N-{4-[(5S,8S,11S,12R)-11-[(2S)-2-butanyl]-12-(2-{(2S)-2-[(1R,2R)-3-{[(1S,2R)-1-hydroxy-1-phenyl-2-propanyl]amino}-1-methoxy-2-methyl-3-oxopropyl]-1-pyrrolidinyl}-2-oxoethyl)-5,8-diisopropyl-4,10-dimethyl-3,6,9-trioxo-2,13-dioxa-4,7,10-triazatetradec-1-yl]phenyl}-N5-carbamoyl-L-ornithinamide; L-Ornithinamide, N-[6-[3-[[(2R)-2-amino-2-carboxyethyl]thio]-2,5-dioxo-1-pyrrolidinyl]-1-oxohexyl]-L-valyl-N5-(aminocarbonyl)-N-[4-[(5S,8S,11S,12R)-12-[2-[(2S)-2-[(1R,2R)-3-[[(1R,2S)-2-hydroxy-1-methyl-2-phenylethyl]amino]-1-methoxy-2-methyl-3-oxopropyl]-1-pyrrolidinyl]-2-oxoethyl]-4,10-dimethyl-5,8-bis(1-methylethyl)-11-[(1S)-1-methylpropyl]-3,6,9-trioxo-2,13-dioxa-4,7,10-triazatetradec-1-yl]phenyl]-; S-(1-(6-(((S)-1-(((S)-1-((4-(((((S)-1-(((S)-1-(((3R,4S,5S)-1-((S)-2-((1R,2R)-3-(((1S,2R)-1-hydroxy-1-phenylpropan-2-yl)amino)-1-methoxy-2-methyl-3-oxopropyl)pyrrolidin-1-yl)-3-methoxy-5-methyl-1-oxoheptan-4-yl)(methyl)amino)-3-methyl-1-oxobutan-2-yl)amino)-3-methyl-1-oxobutan-2-yl)(methyl)carbamoyl)oxy)methyl)phenyl)amino)-1-oxo-5-ureidopentan-2-yl)amino)-3-methyl-1-oxobutan-2-yl)amino)-6-oxohexyl)-2,5-dioxopyrrolidin-3-yl)-L-cysteine

IUPAC Name

(2R)-2-amino-3-[1-[6-[[(2S)-1-[[(2S)-5-(carbamoylamino)-1-[4-[[[(2S)-1-[[(2S)-1-[[(3R,4S,5S)-1-[(2S)-2-[(1R,2R)-3-[[(1S,2R)-1-hydroxy-1-phenylpropan-2-yl]amino]-1-methoxy-2-methyl-3-oxopropyl]pyrrolidin-1-yl]-3-methoxy-5-methyl-1-oxoheptan-4-yl]-methylamino]-3-methyl-1-oxobutan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]-methylcarbamoyl]oxymethyl]anilino]-1-oxopentan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-6-oxohexyl]-2,5-dioxopyrrolidin-3-yl]sulfanylpropanoic acid

Canonical SMILES

CCC(C)C(C(CC(=O)N1CCCC1C(C(C)C(=O)NC(C)C(C2=CC=CC=C2)O)OC)OC)N(C)C(=O)C(C(C)C)NC(=O)C(C(C)C)N(C)C(=O)OCC3=CC=C(C=C3)NC(=O)C(CCCNC(=O)N)NC(=O)C(C(C)C)NC(=O)CCCCCN4C(=O)CC(C4=O)SCC(C(=O)O)N

InChI

InChI=1S/C71H112N12O17S/c1-15-43(8)60(52(98-13)36-55(85)82-35-23-27-51(82)62(99-14)44(9)63(88)75-45(10)61(87)47-24-18-16-19-25-47)80(11)68(93)58(41(4)5)79-66(91)59(42(6)7)81(12)71(97)100-38-46-29-31-48(32-30-46)76-64(89)50(26-22-33-74-70(73)96)77-65(90)57(40(2)3)78-54(84)28-20-17-21-34-83-56(86)37-53(67(83)92)101-39-49(72)69(94)95/h16,18-19,24-25,29-32,40-45,49-53,57-62,87H,15,17,20-23,26-28,33-39,72H2,1-14H3,(H,75,88)(H,76,89)(H,77,90)(H,78,84)(H,79,91)(H,94,95)(H3,73,74,96)/t43-,44+,45+,49-,50-,51-,52+,53?,57-,58-,59-,60-,61+,62+/m0/s1

InChIKey

ZTRDRWJUUWOHKG-QOMYBZJDSA-N

Density

1.3±0.1 g/cm3

Boiling Point

1453.8±65.0°C at 760 mmHg

Cys-MC-VC-PAB-MMAE, a complex molecule integral to targeted cancer therapy through antibody-drug conjugates (ADCs), showcases a myriad of applications. Here are four key applications:

Targeted Cancer Therapy: The strategic use of Cys-MC-VC-PAB-MMAE in ADCs facilitates the precise delivery of the potent cytotoxin MMAE directly to malignant cells. The conjugate’s selective binding to cancer cell antigens enables internalization and controlled release of MMAE within tumor cells. This targeted approach minimizes off-target effects, elevating treatment effectiveness and presenting a promising strategy for battling diverse forms of cancer.

Clinical Oncology Research: Critical for preclinical and clinical investigations, Cys-MC-VC-PAB-MMAE serves as a pivotal tool in assessing the efficacy and safety of novel ADCs. By scrutinizing the pharmacokinetics and pharmacodynamics of these conjugates, scientists can fine-tune dosing schedules and therapeutic windows. This research is fundamental in propelling innovative cancer therapies from experimental phases to practical implementation in clinical environments.

Cell Line Development: Within the realms of biotechnology and pharmaceutical exploration, Cys-MC-VC-PAB-MMAE plays a crucial role in constructing and evaluating engineered cell lines. These engineered cells express specific antigens or receptors, aiding in the evaluation of binding affinity and effectiveness of antibody-drug conjugates. This process assists in the exploration and validation of new therapeutic targets in cancer treatment.

Drug Resistance Studies: Serving as a cornerstone in unraveling drug resistance mechanisms in cancer cells, Cys-MC-VC-PAB-MMAE offers invaluable insights. By subjecting resistant cell lines to this conjugate, researchers can analyze alterations in gene expression, protein levels, and signaling pathways. These revelations are vital for formulating strategies to combat resistance and enhance treatment outcomes in the ongoing battle against cancer.

Catalog	Product Name	CAS
BADC-00019	Fmoc-VC-PAB-MMAE	1350456-56-2
BADC-00849	Acetylene-linker-Val-Cit-PABC-MMAE	1411977-95-1
BADC-01448	mDPR-Val-Cit-PAB-MMAE	1491152-26-1
BADC-00958	Amino-PEG4-Val-Cit-PAB-MMAE	1492056-71-9
BADC-01348	Val-Cit-PAB-MMAE TFA salt	1608127-32-7
BADC-01435	N-Ac-Cys-MC-VC-PAB-MMAE	1628933-80-1
BADC-01408	DBM(C6)-VC-PAB-MMAE	1644228-55-6
BADC-01459	MC-betaglucuronide-MMAE-1	1703778-92-0
BADC-01638	OH-Glu-Val-Cit-PAB-MMAE	1895916-23-0
BADC-00855	SuO-Glu-Val-Cit-PAB-MMAE	1895916-24-1